Pharmacy Times

OCTOBER 3, 2024

By utilizing a lower dose, patients can avoid potential adverse events and high financial burden.

Immunization 96

Immunization 96

Pharmacy Times

JUNE 3, 2025

billion, enhancing community-based oncology care and clinical development. billion, enhancing community-based oncology care and clinical development. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere.

65

65

Pharmacy Times

JUNE 4, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

65

65

Pharmacy Times

APRIL 30, 2024

According to the speaker, the complexity of immune-related adverse events resulting from immune checkpoint inhibitors requires a lot of collaborative discussion between patients and providers.

Immunization 65

Immunization 65

pharmaphorum

NOVEMBER 1, 2024

The 8th Antigen-Specific Immune Tolerance Drug Development Summit is an event organised by Hanson Wade. Discover the latest developments and networking opportunities at this leading industry conference.

Immunization 52

Immunization 52

Pharmacy Times

APRIL 18, 2025

A panelist discusses how waiting for molecular testing results before initiating treatment for nonsmall cell lung cancer (NSCLC) is crucial because patients with EGFR mutations can avoid chemotherapy and immunotherapy in favor of targeted oral agents like osimertinib, which offer survival benefits with minimal toxicity compared to traditional treatments, (..)

Chemotherapy 65

Chemotherapy Immunization 65

Fierce Pharma

JUNE 29, 2023

By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday. While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. |

Vaccines 105

Vaccines Immunization 105

STAT

OCTOBER 14, 2024

Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, reported on Monday that its experimental drug helped patients with a chronic skin condition in an initial and closely watched clinical trial. Among patients given a 120-mg dose, 10 of 12 had a complete response to treatment.

Immunization 115

Immunization 115

pharmaphorum

DECEMBER 4, 2020

The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. The post 4th Antigen Specific Immune Tolerance Summit appeared first on.

Immunization 52

Immunization Medical Schools 52

STAT

DECEMBER 12, 2023

Researchers also found that while adding Darzalex increased the rate of certain side effects, such as diarrhea and low immune cell counts, these adverse events were manageable and didn’t lead to more participants leaving the study. Continue to STAT+ to read the full story…

Immunization 112

Immunization 112

Hospital Pharmacy Europe

JULY 6, 2023

With Hospital Pharmacy Europe ’s inaugural Clinical Excellence in Respiratory Care event in conjunction with Hospital Healthcare Europe fast approaching, there are just a few days left to register. The post Time running out to register for MDT respiratory event appeared first on Hospital Pharmacy Europe.

Hospitals 52

Hospitals Immunization Patient Care 52

pharmaphorum

JANUARY 15, 2021

Latest data give hope that the vaccine could be added to the campaign after phase 1/2a data showed that the shot provided an immune response that lasted for at least 71 days, the duration of time measured in the study involving patients aged 18-55 years. J&J expects to file with the FDA first, followed by other regulators.

Vaccines 119

Vaccines Immunization FDA 119

Pharmacy Times

NOVEMBER 29, 2022

Treatment with immune checkpoint inhibitors have the potential for immune-related adverse events, such as psoriasis.

Immunization 65

Immunization 65

Pharma Times

APRIL 20, 2023

IMM-1-104 found to be well tolerated with no dose limiting toxicities or serious adverse events

Immunization 49

Immunization 49

European Pharmaceutical Review

MARCH 26, 2024

Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition.

Vaccines 110

Vaccines Immunization 110

European Pharmaceutical Review

AUGUST 2, 2023

This is an additional ingredient designed to trigger a stronger immune response. The vaccine demonstrated a strong immune response in the trial. In a clinical trial, this vaccine was shown to faciliate a strong immune response against the Omicron BA.1 1 variant, in addition to the original 2020 strain.

Vaccines 98

Vaccines Immunization 98

Pharmacy Times

DECEMBER 9, 2024

Panelists discuss how bispecific antibody therapies in relapsed/refractory multiple myeloma commonly present with cytokine release syndrome (CRS), immune effector cellassociated neurotoxicity syndrome (ICANS), and increased infection risks, while talquetamab specifically exhibits distinctive adverse events including nail changes, skin reactions, and (..)

Immunization 65

Immunization 65

Pharmacy Times

DECEMBER 6, 2022

Biomarker testing and management of immune-related adverse events are key roles for pharmacists.

Immunization 65

Immunization 65

PharmaShots

APRIL 5, 2023

Shots: The P-IIb dose-finding study evaluates vidofludimus calcium vs PBO in patients at 78 study sites in the US and EU The 50wk. maintenance phase results showed a dose-linear increase in clinical remission, 10 & 30mg, qd of vidofludimus calcium showed clinical remission rate (42.3% & 61.5%

Immunization 40

Immunization 40

Pharmaceutical Technology

NOVEMBER 14, 2022

In lupus, the body’s immune system starts to attack its own cells. Saphnelo is also being studied in a Phase III trial in lupus nephritis, where a person’s immune system targets the kidneys, eventually leading to kidney failure. As per AstraZeneca's recent Q3 earnings, Saphnelo has yielded $69 million to date this year.

Immunization 144

Immunization FDA 144

Hospital Pharmacy Europe

JULY 18, 2023

The primary outcome of interest was a physician-verified positive immune-mediated oral penicillin challenge within one hour after the intervention. In the five days following the oral penicillin challenge, a total of nine immune-mediated adverse events were recorded in the intervention group and 10 in the control group.

Immunization 98

Immunization Labelling Hospitals 98

European Pharmaceutical Review

JUNE 27, 2023

Participants with greater than 90 days of follow-up had elimination of severe hypoglycaemic events in the evaluation period. It is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. This eliminates the need for immunosuppression.

Immunization 98

Immunization 98

European Pharmaceutical Review

JULY 13, 2023

The field of immunotherapy is constantly evolving with the ultimate goal to develop new treatments that help the body’s immune system fight cancer. Immune cells, such as T cells and natural killer (NK) cells, have the inherent ability to combat diseases, including cancer, but are often inhibited by the body’s own suppressive mechanisms.

Immunization 98

Immunization Hospitals FDA 98

pharmaphorum

NOVEMBER 27, 2024

The 10th Innate Killer Summit is a premier event organised by Hanson Wade, bringing together experts and thought leaders in the field of innate immunity and natural killer cells. Learn more about this event and how it can benefit you.

Immunization 52

Immunization 52

pharmaphorum

APRIL 12, 2021

Preclinical and early clinical data for modulators of the STING & TLR plus other innate immune checkpoint inhibitors has been hugely promising. View the event guide now for the full agenda details and speaker faculty. View the full event guide now. The post STING & TLR Targeting Therapies Summit appeared first on.

Immunization 52

Immunization 52

The Checkup by Singlecare

AUGUST 29, 2024

How Dupixent works in the body It’s still unclear what causes atopic dermatitis , the most common form of adult and pediatric eczema, but it’s commonly regarded as an immune system and skin barrier condition. Those intruders trigger the immune system, which releases certain proteins that cause skin inflammation.

Immunization 97

Immunization Documentation Labelling 97

pharmaphorum

SEPTEMBER 11, 2022

With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”

Immunization 105

Immunization Chemotherapy Hospitals 105

pharmaphorum

FEBRUARY 8, 2021

It works by using inactivated viral particles to expose the immune system, which mounts an immune response that fights off the active virus in the event of an infection. Brazilian clinical trial results published last month showed the vaccine, dubbed Coronavac, is just over 50% effective.

Vaccines 90

Vaccines Immunization 90

European Pharmaceutical Review

OCTOBER 25, 2024

The monoclonal antibody therapy was reported to be well tolerated, with most treatment emergent adverse events (TEAE) Grade 1 or 2, according to the findings. These promising data support continued evaluation of ZL-1310 as a monotherapy in the dose-expansion phase of the ongoing Phase I clinical trial and in combination.”

Chemotherapy 97

Chemotherapy Compounding Immunization 97

European Pharmaceutical Review

SEPTEMBER 22, 2022

The removal of HIV DNA from the cellular genome is essential to effecting a cure; the virus takes up long-term residence in tissue reservoirs, where it hides, evading the immune system and escaping antiretroviral therapy. As a result, HIV can persist in tissue reservoirs for years.

Labelling 145

Labelling Immunization 145

pharmaphorum

APRIL 16, 2021

The 2 nd Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better modulate, measure and predict immune response to your gene therapy candidate. View the full event guide now for full meeting details! Regulatory considerations for immune responses to gene therapies with the US FDA.

Immunization 52

Immunization FDA 52

pharmaphorum

NOVEMBER 15, 2021

Arriving at a critical point for TIGIT development, the 2nd Annual TIGIT Therapies Summit is the definitive industry-led event focused on propelling this next-generation inhibitor to clinical use. Plus 2 add on workshops: • Elucidating the anti-tumor immunity of other immune checkpoint inhibitors in oncology.

Medical Schools 52

Medical Schools Immunization Hospitals 52

pharmaphorum

NOVEMBER 29, 2022

Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. No serious adverse events were observed.

Immunization 105

Immunization Chemotherapy Compounding FDA 105

pharmaphorum

MAY 3, 2022

Learn all there is to know about the immune cell engager landscape, including clinical achievements, potential response predictors, and novel immune cell-based engager therapeutic discoveries. Download the full event guide to find out more. The post 4th Annual Cell Engager Summit | May 24-26 | Boston, MA appeared first on.

Immunization 52

Immunization 52

European Pharmaceutical Review

OCTOBER 7, 2022

UC is an Inflammatory Bowel Disease (IBD) that makes immune system attack the gastrointestinal (GI) tract. Zeposia ® reduces the capacity of lymphocytes to emerge from lymph nodes, reducing the number of lymphocytes (immune cells created in blood marrow) circulating in the blood. percent versus 6 percent. percent vs 18.5 percent vs 5.6

Immunization 98

Immunization 98

pharmaphorum

AUGUST 31, 2022

In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.

Chemotherapy 116

Chemotherapy Immunization Hospitals 116

pharmaphorum

MAY 10, 2021

At the moment, there’s no indication that the cases are linked to the vaccine itself, but the EMA has asked the companies to provide “further detailed data, including an analysis of the events according to age and gender,” as it looks into the signal.

Vaccines 122

Vaccines Labelling Immunization 122